Dyne Therapeutics (NASDAQ:DYN) Issues Earnings Results, Beats Estimates By $0.04 EPS

Dyne Therapeutics (NASDAQ:DYN) issued its quarterly earnings data on Tuesday. The company reported ($0.88) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.04, Zacks reports.

Dyne Therapeutics Price Performance

DYN stock opened at $12.18 on Thursday. The business’s 50-day moving average is $16.51 and its two-hundred day moving average is $27.03. The firm has a market capitalization of $1.24 billion, a P/E ratio of -3.42 and a beta of 1.11. Dyne Therapeutics has a 1 year low of $11.62 and a 1 year high of $47.45.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, SVP Richard William Scalzo sold 1,455 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $40,914.60. Following the sale, the senior vice president now directly owns 127,078 shares in the company, valued at $3,573,433.36. This trade represents a 1.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Oxana Beskrovnaya sold 2,334 shares of the company’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $65,632.08. Following the transaction, the insider now directly owns 201,685 shares of the company’s stock, valued at approximately $5,671,382.20. This represents a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 6,387 shares of company stock valued at $142,789. 20.77% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

DYN has been the topic of several recent analyst reports. Piper Sandler decreased their price target on Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $45.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. Baird R W raised shares of Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. Raymond James raised shares of Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Finally, Chardan Capital reissued a “buy” rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research report on Friday, February 28th. One analyst has rated the stock with a sell rating, one has issued a hold rating, ten have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Dyne Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $48.64.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.